Journal of Antibiotics
A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia
Tsarenko S. V.
1, 2
,
Zigangirova N A
3
,
Soloveva A V
3
,
Bondareva Nataliya E
3
,
Koroleva E A
3
,
Sheremet Anna B
3
,
Kapotina L N
3
,
Shevlyagina N V
3
,
Andreevskaya S G
3
,
Zhukhovitsky V G
3
,
Filimonova E V
2, 4
,
Gintsburg A. L.
3, 5
1
National Medical Research Center “Treatment and Rehabilitation Center of the Ministry of Health of the Russian Federation, Moscow, Russia
|
4
State Budgetary Healthcare Institution “Moscow City Clinical Hospital № 52 of Moscow Healthcare Department” (MCCH52), Moscow, Russia
|
Publication type: Journal Article
Publication date: 2023-04-21
Journal:
Journal of Antibiotics
Quartile SCImago
Q2
Quartile WOS
Q2
Impact factor: 3.3
ISSN: 00218820, 18811469
Drug Discovery
Pharmacology
Abstract
The problematic treatment of infections caused by multiple-resistant Klebsiella, especially in ICU, is the leading cause of prolonged hospitalization and high mortality rates. The use of antibiotics for the prevention of infections is considered unreasonable as it may contribute to the selection of resistant bacteria. In this regard, the development of drugs that will be effective in preventing infection during various invasive procedures is extremely necessary. We have shown that the developed innovative antibacterial compound fluorothiazinone (FT) that suppresses the formation of biofilms is effective in the prevention of a model pneumonia caused by a multi-resistant clinical K. pneumoniae isolate. Prophylactic use followed by treatment with FT in mice with acute pneumonia modulates the local innate immune response without suppressing protective properties in the early stages of infection, while contributing to a decrease in the bacterial load in the organs and preventing lethal pathological changes in the lungs at later stages of K. pneumoniae infection. Further development of such antivirulence drugs and their use will reduce morbidity and mortality in nosocomial infections, as well as reduce the number of antibiotics used.
Citations by journals
|
1
|
|
|
Journal of Pharmaceutical and Biomedical Analysis
|
Journal of Pharmaceutical and Biomedical Analysis
1 publication, 25%
|
|
Safety and Risk of Pharmacotherapy
|
Safety and Risk of Pharmacotherapy
1 publication, 25%
|
|
Journal of Antibiotics
|
Journal of Antibiotics
1 publication, 25%
|
|
Arabian Journal of Chemistry
|
Arabian Journal of Chemistry
1 publication, 25%
|
|
1
|
Citations by publishers
|
1
2
|
|
|
Elsevier
|
Elsevier
2 publications, 50%
|
|
Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP)
|
Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP)
1 publication, 25%
|
|
Springer Nature
|
Springer Nature
1 publication, 25%
|
|
1
2
|
- We do not take into account publications that without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
{"yearsCitations":{"type":"bar","data":{"show":true,"labels":[2023,2024],"ids":[0,0],"codes":[0,0],"imageUrls":["",""],"datasets":[{"label":"Citations number","data":[2,2],"backgroundColor":["#3B82F6","#3B82F6"],"percentage":["50","50"],"barThickness":null}]},"options":{"indexAxis":"x","maintainAspectRatio":true,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":1,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Citations per year","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"journals":{"type":"bar","data":{"show":true,"labels":["Journal of Pharmaceutical and Biomedical Analysis","Safety and Risk of Pharmacotherapy","Journal of Antibiotics","Arabian Journal of Chemistry"],"ids":[23304,30293,6099,18459],"codes":[0,0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/YHqSxURcCyJMSz32EZgqANhIyx2l98KyZGPojkY9_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp","\/storage\/images\/resized\/9z7b0TQJNgUxZHYXLrTmbnjJn9y5iq56Wxtqb1Lv_medium.webp"],"datasets":[{"label":"","data":[1,1,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6","#3B82F6"],"percentage":[25,25,25,25],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Journals","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}},"publishers":{"type":"bar","data":{"show":true,"labels":["Elsevier","Scientific Center for Expert Evaluation of Medicinal Products (SCEEMP)","Springer Nature"],"ids":[17,7724,8],"codes":[0,0,0],"imageUrls":["\/storage\/images\/resized\/GDnYOu1UpMMfMMRV6Aqle4H0YLLsraeD9IP9qScG_medium.webp","\/storage\/images\/resized\/YHqSxURcCyJMSz32EZgqANhIyx2l98KyZGPojkY9_medium.webp","\/storage\/images\/resized\/voXLqlsvTwv5p3iMQ8Dhs95nqB4AXOG7Taj7G4ra_medium.webp"],"datasets":[{"label":"","data":[2,1,1],"backgroundColor":["#3B82F6","#3B82F6","#3B82F6"],"percentage":[50,25,25],"barThickness":13}]},"options":{"indexAxis":"y","maintainAspectRatio":false,"scales":{"y":{"ticks":{"precision":0,"autoSkip":false,"font":{"family":"Montserrat"},"color":"#000000"}},"x":{"ticks":{"stepSize":null,"precision":0,"font":{"family":"Montserrat"},"color":"#000000"}}},"plugins":{"legend":{"position":"top","labels":{"font":{"family":"Montserrat"},"color":"#000000"}},"title":{"display":true,"text":"Publishers","font":{"size":24,"family":"Montserrat","weight":600},"color":"#000000"}}}}}
Metrics
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Tsarenko S. V. et al. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia // Journal of Antibiotics. 2023.
GOST all authors (up to 50)
Copy
Tsarenko S. V., Zigangirova N. A., Soloveva A. V., Bondareva N. E., Koroleva E. A., Sheremet A. B., Kapotina L. N., Shevlyagina N. V., Andreevskaya S. G., Zhukhovitsky V. G., Filimonova E. V., Gintsburg A. L. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia // Journal of Antibiotics. 2023.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1038/s41429-023-00621-2
UR - https://doi.org/10.1038%2Fs41429-023-00621-2
TI - A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia
T2 - Journal of Antibiotics
AU - Tsarenko, S. V.
AU - Zigangirova, N A
AU - Soloveva, A V
AU - Bondareva, Nataliya E
AU - Koroleva, E A
AU - Sheremet, Anna B
AU - Kapotina, L N
AU - Shevlyagina, N V
AU - Andreevskaya, S G
AU - Zhukhovitsky, V G
AU - Filimonova, E V
AU - Gintsburg, A. L.
PY - 2023
DA - 2023/04/21 00:00:00
PB - Springer Nature
SN - 0021-8820
SN - 1881-1469
ER -
Cite this
BibTex
Copy
@article{2023_Tsarenko,
author = {S. V. Tsarenko and N A Zigangirova and A V Soloveva and Nataliya E Bondareva and E A Koroleva and Anna B Sheremet and L N Kapotina and N V Shevlyagina and S G Andreevskaya and V G Zhukhovitsky and E V Filimonova and A. L. Gintsburg},
title = {A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia},
journal = {Journal of Antibiotics},
year = {2023},
publisher = {Springer Nature},
month = {apr},
url = {https://doi.org/10.1038%2Fs41429-023-00621-2},
doi = {10.1038/s41429-023-00621-2}
}